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ABSTRACT 
 
Evaluation of the Effectiveness of the International Index of Erectile Function (IIEF-5) 
(SHIM) Questionnaire on the Diagnosis and Treatment of Erectile Dysfunction  
 
Evelyn Martin 
 
Thirty million or 52% of males between 40 and 70 years of age in the United States have some 
degree of erectile dysfunction (ED) (Feldman et al., 1994; Hakim, Subit, Kandzari, & ZasLau, 
2002; Tsertsvadze et al., 2009).  The American Urology Association (AUA) outlines measures to 
slow the rate of, control, and treat ED.  To decrease the prevalence, ED must be diagnosed, 
identified, and the major risk factors aggressively controlled.  Utilization of clinical practice 
guidelines (CPGs) may improve identification and documentation of treatment, but questions 
remain about how to implement CPGs in practice. The purpose of this pilot project was to 
evaluate the effectiveness of the International Index of Erectile Function (IIEF-5) questionnaire 
on the diagnosis and treatment of ED in two primary care rural clinics in West Virginia. Through 
the use of Diffusion of Innovation Theory, the IIEF-5 questionnaire was utilized and 
implemented into the clinics. This study used a descriptive design with pre and post chart 
reviews and a convenience sample of 121 male patients 40-70 years old.  Clinicians and staff 
were oriented to the use of a screening instrument before its implementation. The questionnaire 
was piloted for six-weeks. Data from chart reviews were collected from 50 randomly selected 
charts pre and 89 charts post implementation. Of the 89 post implementation charts, only 71 
were eligible for the pilot project. The pre implementation prevalence was 5/50 (10%) and 
documentation for treatment of ED pre implementation was 2/5 (40%). Post implementation the 
prevalence of ED was 53/71 (75%) and documentation of treatment options in those completing 
  
the questionnaire was 42/53 (79%).  There were no significant differences in ages for males 50 to 
70 years between the pre and post implementation group (0.6). However, there was a statistical 
significant difference between the pre and post implementation males < 49 years of age. In 
Group 1 – 21/50 (42 %) of the men were <49; Group 2 – 4/71(5.6%) were < 49 years. Prevalence 
of ED in Group 1 - participants 50 - 70 years of age was 5/29 (17%), while prevalence of ED in 
Group 2 - participants 50 - 70 years of age was 50/66 (76%). There was one participant in the 
group with an unknown age. All 71 (100%) questionnaires were scanned into the patient’s charts 
and a diagnosis of ED was added to the patients list of health care issues.  The use of the IIEF-5 
questionnaire in primary care clinics is an effective tool for evaluating the diagnosis and 
treatment of ED and can easily be incorporated into the patients’ charts.   
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 1 
Evaluation of the Effectiveness of the International Index of Erectile Function (IIEF-5) 
(SHIM) Questionnaire on the Diagnosis and Treatment of ED 
ED (ED) is one of the most common diseases of male sexual dysfunction. For a male, it 
can also be a very distressing condition. ED is a health issue that affects the physical, mental, 
social well-being, and the interpersonal relationships of the afflicted patients (Canadian 
Guidelines Towards Optimized Practice [TOP], 2009; Feldman, Goldstein, Hatzichristou, Krane, 
& McKinlay, 1994; Hatzimouratidis et al., 2010; Hwang, Tsai, Lin, Chiang, & Chang, 2010; 
Jonas, 2001). The National Institutes of Health (NIH) Consensus Development Conference on 
Impotence (1993) definition of ED is a continual failure to attain or retain an erection adequate 
for satisfying sexual intercourse (Feldman et al., 1994; Yamada, Hara, Umematsu, Suzuki & 
Kadowaki, 2012).  The designation ED is the preferred newly adopted term as opposed to the 
previously used term “impotence”. ED is more appropriate because a male may continue to have 
sexual desire and be able to have an orgasm with his ejaculate unimpaired regardless of the 
failure to get or keep an erection (Montague et al., 2009). ED can produce emotional and 
interpersonal relationship difficulties, and frequently leads to poor self-esteem, low self-
confidence, and withdrawal from partners, thereby affecting the patient’s quality of life (Hwang 
et al., 2010). 
Background and Significance 
According to the Massachusetts Male Aging Study (MMAS), the best estimate for 
prevalence of ED is 52% or 30 million men in the United States between 40 and 70 years of age 
(Feldman et al., 1994; Hakim, Subit, Kandzari, & ZasLau, 2002; Tsertsvadze et al., 2009). A 
sample size of 1700 male participant’s ages 40-70 years were included in the MMAS study 
(Feldman et al., 1994).  A later study by the United States Department of Health and Human 
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Services, Centers for Disease Control and Prevention, and the National Center for Health 
Statistics (2001-2002), the National Health and Nutrition Examination Survey (NHANES 2001-
2002) looked at a group of 2126 male participants > 20 years and found the incident rate to be 
lower: 427 (20.1%) male participants age 40-70 years with ED. One major factor in the 
prevalence of ED is age with the occurrence of ED growing from 5% among men age 40 to 15% 
among those 70 years of age. The MMAS also gives a conservative worldwide projection of 322 
million cases by 2025 based upon age specific prevalence estimates (Aytac, McKinlay, & Krane, 
1999; Tsertsvadze et al., 2009).  The incidence of ED is higher in men with comorbidities such 
as: diabetes, hypertension, arterial insufficiency, high cholesterol levels, stress, mental health 
issues, and spinal cord injuries (Johannes, Araujo, Feldman, Derby, Kleinman, & McKinlay, 
2000). As the population of the United States continues to age, ED is likely to become a more 
prevalent issue for men. Although there is a lot of information about the pathophysiology of ED, 
relatively little is known about how ED affects men's daily lives. 
The financial cost of ED is extensive. According to Litwin, & Saigal (2007), in 2000 the 
estimated number of provider visits by men 18 and older living in the United States with a 
diagnosis of ED was 2.9 million. Pfizer reported the United States sales for Viagra, a 
phosphodiesterase-5 inhibitor (PDE-5) for the year 2008 were $897 million with worldwide sales 
for the same year at $1.9 billion (Pfizer, 2009). Similarly, the United States sales for Cialis, a 
second PDE-5 inhibitor, for the year 2009 were $623.3 million, and worldwide sales totaled $1.6 
billion for the same year (Tolliver, personal conversation, Jan. 15, 2011). Likewise, the revenue 
for Levitra, the third PDE-5 inhibitor for 2009 totaled $360 million (Bayer, 2009). Other revenue 
is generated through black market sales of these medications. Additionally, the annual cost for 
evaluation and treatment of ED was $327 million (Tsertsvadze et al., 2009). In a region in 
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Southern West Virginia, the 2009 sales for Viagra, one of the three well-known PDE–5 
inhibitors, totaled $839, 000 (Bright, personal conversation Jan. 15, 2011).  
While the healthcare burden of ED is not as significant as that of diabetes or 
cardiovascular disease, it is still a burden to the patient. Factors contributing to erectile 
dysfunction include those that are both psychological and physical in nature (Montague et al., 
2009).  Psychological factors include anxiety, stress depression, even the idea of failure causes 
performance anxiety (Montague et al., 2009).  Physical factors contributing to the erectile 
dysfunction in men include diabetes, arterial and vascular disease, penile nerve damage, sacral 
nerve damage, hormone imbalance, Peyronie’s disease.  Social and lifestyle factors contributing 
to erectile dysfunction include heavy smoking, drinking or drug abuse, obesity, in addition to, 
high cholesterol. (Montague et al., 2009).  Statistics of patients having both ED and specific co-
morbidities found in the United States are as follows: vascular (40%), diabetes mellitus (30%), 
ED after radical surgery (13%), spinal cord injuries and other traumas (8%), other endocrine 
problems (6%), and multiple sclerosis (3%) (“Statistic of erectile dysfunction in US,” 2011).  
Other considerations include: the related cost of office visits to providers, tests to rule out 
other factors, the diagnosis of ED, hormone therapy, intracavernous injections, vacuum erectile 
devices, penile implants, and implant surgery.  As previously mentioned, according to Hwang et 
al. (2010) ED can produce emotional and interpersonal relationship difficulties, and frequently 
leads to poor self-esteem, low self-confidence, and withdrawal from partners, thereby affecting 
the patient’s quality of life. With these psychological causes of ED, various factors can affect 
sexual emotions and affect or worsen ED including:  anxiety, depression, or other mental health 
conditions, stress and the interrelationship issues created by stress (Cappelleri & Rosen, 2005; 
Hwang et al., 2010). Furthermore, the cost for depression and anxiety medications, in addition to 
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the clinical visits to providers for treatment, are also included in the financial burden of ED. Not 
included in the financial burden but a cost in itself is what ED does to the afflicted patient’s self-
esteem, self-confidence, and interpersonal relationships.  
Internal medicine and/or family practice physicians and practitioners are frequently the 
initial provider with whom the patient has contact to talk about ED. According to a study by 
Rutchik et al. (2000), the prevalence of sexual diseases and issues in patients seen by primary 
care physicians and internist has been estimated to be as high as 34%. In southern West Virginia, 
an evaluation of the prevalence of ED complaints and the use of a validated questionnaire for the 
diagnostic assessment of ED had not been performed. 
 Theoretical Framework 
The theoretical framework chosen to guide this pilot project was Rogers Diffusion of 
Innovations theory. Diffusion of Innovations illustrates ways to describe how a population would 
receive an innovation (Rogers, 2003). There are three important observations in the development 
of community change: traits that make an innovation flourish effectively, the significance of 
peer-to-peer dialogues and peer groups, and accepting the needs of a diverse population. Rogers 
designed the conceptual foundation in 1962 to describe why, how, and at what pace new 
concepts and technology would circulate throughout an organization. Contributions of diffusion 
research have been included into other disciplines including: communications, public relations, 
social psychology, consumer behavior, rural sociology, and public health (Rogers, 2003). As 
compared to most other theories of change, Diffusion of Innovations takes a different direction. 
Diffusion of Innovations’ prime focus is concerned with the spread of innovations and behaviors 
to better support the needs of the population. In Diffusion of Innovations it is not the population 
that changes, but the innovations themselves (Rogers, 2003).     
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Relative advantage is the degree to which a specific population, such as a clinic, 
recognizes an innovation as better than the idea, product, or way of doing something it replaces. 
The better the apparent relative advantage of an innovation, the quicker the innovation’s rate of 
adoption may be (Rogers, 2003).   
According to Rogers (2003), there are four key elements in the Diffusion of Innovations 
theory. The key elements of diffusion are: (1) innovation, (2) communication channels, (3) time, 
and (4) social system. If the innovation is adopted, it extends by means of an assortment of 
communication channels. Throughout communication, innovations are seldom gauged from a 
scientific point of view; more accurately, individual opinions of the innovation sway diffusion. 
As the sites for this project were both relatively small clinics, the investigator tailored the project 
design to meet the clinic’s needs.  
Rogers (2003) describes an innovation as an idea, action, or entity that an audience 
perceives as new. As neither of the clinics chosen for this pilot project was using a measurement 
tool for identifying ED, this theory supported the implementation of a pilot practice change for 
assessing, identifying, and documentation of treatment options to patients with ED.  The 
providers were trained on the use and scoring of the IIEF–5 questionnaire.  
The second element, diffusion is a special type of communication where the information 
traded relates to the new idea. The second element, communication channels, is where the 
providers accept the idea of utilizing the measurement tool and pass the idea on to others 
(Rogers, 2003). In addition, during the communication channel the participants were informed of 
the project. Implementation of the project occurred for a six-week period in two clinics in 
southern West Virginia. A baseline chart review of 50 charts was completed at the beginning of 
the innovation. At the end of the implementation period, another 89 charts were reviewed and 
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assessed to determine whether the questionnaires were being used for diagnostic assessment and 
if so, was there documentation of treatment options. Communications relating to this project 
were in verbal and written form to present specific information to the providers. Communication 
was essential for the success of the pilot project. The investigator completed an educational 
meeting with the physicians one week prior to implementing the pilot project. During the six-
week pilot project period, communication was principally initiated by the investigator. In 
addition, there were no issues or questions concerning the project voiced during follow-up 
communication.  The physicians were both pleased at how well the project was going and the 
value of the project for their respective patients. 
The third element, time, affected this project in that there was a six-week pilot period for 
the providers to become familiar with the IIEF-5 and begin using this tool with the clinics’ 
patients. The diffusion process takes place over time (Rogers, 2003). As this was a pilot project, 
the short duration was vital as the limited time gave the providers an idea of how quickly the 
project could be implemented, and how quickly the project could become successful. Time starts 
with the knowledge of the new idea and goes through the final acceptance and implementation or 
rejection of the new idea. Time also encompasses the rate of adoption and is affected by five 
distinct groups of adopters, from innovators and early adopters through early and late majority to 
laggards (Rogers, 2003).  
Rogers describes a social system that can be applied to the clinic environment. The social 
system as defined by Rogers is a set of interconnected parts that are joined in shared problem 
solving to achieve a common goal. The social system decides diffusion, norms on diffusion, the 
tasks of opinion leaders and change agents, varieties of innovation decisions, and innovation 
consequences. To utilize Rogers’ model in a health care setting requires one to presume that the 
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innovation in classical diffusion theory is comparable with scientific research findings in the 
framework of practice, a supposition that has not been carefully tested (Rogers, 2003).  
In addition to the five stages, Rogers (2003) also describes five adopter categories. 
The rate of innovation adoption is determined primarily by the adopter category. The adoption of 
an innovation follows an S curve when mapped out over a length of time. Rogers defines the 
five-adopter categories: innovators, early adopters, early majority, late majority, and laggards.  
Innovators are those participants in a system who quickly adopt an innovation. This 
usually encompasses the first two and one-half percent. Innovators are described as those that are 
willing to take a risk, are adventurous, and have leadership attributes and qualities. The 
investigator in this project sought to gain favor with the providers at the clinics, as the providers 
appeared to be potential innovators. The provider in the clinic in Charleston, West Virginia has 
an interest in new ideas and tends to step outside the typical realm of a family practice provider. 
The other clinic provider is more established and was not looking for new ideas to help expand 
his practice, but was willing to try the pilot project to see if the use of a questionnaire would 
benefit his patients. Although this innovation was implemented as a pilot project, both providers 
were willing to take the risk to improve communication with the patients on such a sensitive 
subject.  
Early adopters are the solid members of the communities. When the early adopter accepts 
an idea, this is usually the “stamp” of approval for others to adopt the idea. Early adopters follow 
the innovators and make up the next 13.5 percent of participants in a system to adopt an 
innovation. Because early adopters are considered to be leaders, they are sought after by change 
agents. 
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Early majorities are those that adopt new ideas before most in the community, but are 
never the leaders. They make up 34 percent of the members in the system and usually 
contemplate the idea for a while before moving to acceptance. The early majority typically 
adopts a new innovation or idea before the regular members of the organization, but only after 
careful reflection. Late majority members are the skeptics. They make up the next 34 percent of 
the members in the system and usually adopt for economic reasons or due to peer pressure. They 
approach new ideas with skepticism and caution, and do not usually adopt until almost everyone 
else in the system has adopted the idea.  
Finally, laggards look to the past, identifying what has previously worked. They tend to 
be distrustful of new ideas and of change and hold out until the very end. Laggards want to be 
sure that the innovation will be worth their effort. They also see the adoption of specific 
innovations as a high risk and are afraid to move forward (Rogers, 2003). Laggards make up the 
last 16 percent of the individuals in a system to adopt an innovation.  
Another concept of Rogers’ model (2003) that needs to be explained and defined for this 
project is the innovation-decision process. An individual moves from first acquiring knowledge 
of an innovation to the formulation of a mindset toward the innovation, to making a decision to 
adopt or reject, to implementing the new idea, then to confirming this decision during that 
progression. Rogers’ five-stage adoption progression consists of: 1) the knowledge or awareness 
step; 2) the persuasion step; 3) the decision or evaluation step; 4) the implementation or trial 
step; 5) the confirmation or adoption step.  
The first step of this pilot project was the knowledge or awareness step, where the 
individuals were made aware of the innovation but needed more information (Rogers, 2003). The 
knowledge step included reviewing the guidelines for diagnosis and treatment of ED with the 
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providers, as well as providing information on the use of the IIEF-5 tools for diagnostic 
evaluation of the degree of ED and for detecting treatment related changes in patients with ED. 
During the knowledge step, the investigator discussed findings from the clinics’ chart reviews. 
There are three types of knowledge concerning an innovation. The first is awareness-knowledge. 
This is information that an innovation exists. In this project, the investigator described the project 
to the providers at the clinics, defining what was needed and how the project was to be 
implemented. The next type is the how-to-knowledge. Throughout this type of knowledge, the 
investigator went over what was necessary to make the project work correctly and made sure the 
providers understood. The last type of knowledge is principles-knowledge. During this type of 
the knowledge, the investigator explained how the innovation worked. It was imperative that the 
providers knew the steps that it would take to make the project a success for the clinic, patients, 
and the investigator. The investigator took the time to explain the importance of the innovation 
and the importance of the role of the providers.  
The second step is the persuasion step. This is where the individual becomes interested in 
the new idea and wants to find out more about the innovation (Rogers, 2003). In addition, those 
who come onboard earlier in the process can be used to help persuade those still not sure about 
adopting the innovation. During this step, the investigator took time and discussed the project 
with the providers, explaining why the project was so important and that by adopting the IIEF-5 
their identification of new patients with ED would benefit the practice by potentially creating 
additional revenue with more office visits, potential new patients, and better satisfied patients 
overall. In addition, during this step the providers would decide that the project was either 
something they would adopt or that it was too time consuming, too costly, or just not a good fit 
for their clinics.  
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The third step is the decision or evaluation step. This is when the individual gathers more 
information and can think about applying the innovation to current and anticipated future 
circumstances. The decision step is another step where the individual or organization can choose 
whether to adopt or reject the innovation (Rogers, 2003). The decision step occurred when the 
providers scanned the IIEF-5 into the patient’s chart. This step offered another chance to make 
necessary changes, to see who was onboard, and to take steps towards changing the minds of 
those not onboard. The investigator was prepared to “sell” the project even more during this step. 
Rogers suggests that although the innovation may be accepted or rejected at any time during the 
project, it is usually during this step that this happens. Rogers further defines adoption as the 
choice to make complete use of an innovation as the best route of action, and rejection as a 
choice not to adopt an innovation. If the organization chooses to adopt, then a decision is made 
on the best course of implementing the innovation. If the organization chooses to reject, then the 
decision is made not to adopt the innovation.  
The fourth step is the implementation or trial stage. This is when the individual applies 
the new idea (Rogers, 2003). In addition, this was also when the provider’s behavior changed 
with the actual implementation of the project (Rogers, 2003). Implementation occurred when the 
providers decided that the tool was useful to the clinic’s practice. The providers decided to 
routinely use the tool with every male patient, scan the tool into the charts, and to schedule 
follow-up appointments for those with a diagnosis of ED as identified by the tool. The decision 
to use the IIEF-5 in these clinics was easy, but sometimes actually putting the innovation in place 
may cause unique problems. During this step, the investigator needed to be available to answer 
any issues not previously addressed.  
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The last step, the confirmation or adoption step is when the individual decides the new 
idea is of benefit and continues to use the innovation. The confirmation step occurred when the 
providers ascertained the benefits and incorporated the innovation into the system (Rogers, 
2003). This step occurred when the project became protocol for men visiting the clinics. Rogers 
suggests that the confirmation step does not have to be the end step; that the providers may seek 
reinforcement and may have a change of mind about the decision. During this step, the concept 
of reinvention occurs. The project could have been changed and reintroduced back to the clinic if 
necessary through reinvention. With reinvention, the individual or organization may change or 
modify the innovation during the adoption or implementation process (Rogers, 2003). If the 
project is adopted and used after the diffusion project is terminated, then this is considered to be 
sustainability. Discontinuance is what happens when the providers adopt the idea but then decide 
not to continue using the innovation. Discontinuance has two types: 1) replacement 
discontinuance is the rejection of the idea in order to adopt a newer, better idea, or 2) 
disenchantment discontinuance is the rejection of the idea because the innovation was not what 
was wanted or expected, or there was dissatisfaction with the innovation’s performance (Rogers, 
2003). In the case of the two clinics in this pilot project, both providers were happy with the 
innovation and were pleased to adopt the use of the IIEF-5 questionnaire into their practice.   
According to Rogers (2003), the rate of adoption is identified as the relative speed with 
which individuals in a social system adopt an innovation. The rate is typically measured by the 
amount of time needed for a specific percentage of the individuals in a social system to adopt an 
innovation. Rogers (2003) describes five attributes that affect the rate of adoption: 1) 
observability or the degree to which the results of a new idea are evident to potential adopters; 2) 
relative advantage or the degree to which the innovation is considered superior to current 
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practice; 3) compatibility or the degree to which the innovation is perceived to be consistent with 
socio-cultural values, previous ideas, and/or perceived needs; 4) trialability or the degree to 
which the innovation can be experienced on a limited basis; 5) complexity, the degree to which 
an innovation is difficult to use or understand its simplicity.  
Observability of this project may prove measureable now that the providers have seen 
what the project entails and the results of the short pilot. With the implementation of the project, 
the providers may begin talking about it to their peers, and others may adopt this innovation for 
their practices. Relative advantage will be recognized once the patients and providers realize the 
gains from the innovation. Prior to the project, neither clinic utilized a measurement tool; 
therefore, the addition of the IIEF-5 questionnaire will be a valuable addition. Gathering baseline 
data from the clinics prior to the implementation of the project allowed the investigator to show 
how beneficial the IIEF-5 could be to the clinics. As the innovation produces not only revenue 
for the clinics, but potential new diagnoses and treatments of ED in patients, adoption may be 
welcomed. Relative advantage and compatibility of the project with one of the clinics was that 
the provider utilizes a similar questionnaire for menopausal problems in women coming into the 
practice; therefore, training was minimal. In addition, as the IIEF-5 measurement tool is one that 
the patients can answer themselves in the privacy of their examination room, while waiting for 
the providers. There will be minimal increased workload or time commitment involved.  
Finally, the providers and patients made this project a success by working together to 
address this innovation. At any point during the pilot period, the providers were given the 
opportunity to voice their opinion on the project, suggest changes, discuss what they didn’t like, 
and discuss whether or not this was a viable project for their clinics. The investigator met or 
spoke with the providers every other week to allow for feedback. The investigator also provided 
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phone numbers and email addresses to the providers for use if there were any questions or 
problems that arose prior to the meetings. 
Although the Diffusion of Innovations theory is an appropriate model for presenting 
clinical guidelines or practice changes, there are potential issues in the use of the theory for this 
practice change. Even though the guidelines suggesting the use of the validated IIEF-5 
questionnaires exist, to have them adopted in a clinical setting may take some time. As more 
research demonstrates the benefits of using the IIEF-5 for the providers and patients, the 
adoption may come more quickly. Expectation of a swift adoption and execution may cause 
problems in the system, which inevitably may cause the project to fail or be rejected.  
The benefit of the Diffusion of Innovations theory has been realized in the medical, 
educational, organizational, community, and practice settings. Most of the new ideas whose 
diffusion has been analyzed are technological innovations. Frequently when using the Diffusion 
of Innovations theory, an organization will not get instant gratification; however, with this 
project utilization of the IIEF-5 demonstrated a quick method of acquiring results. The Diffusion 
of Innovations theory is an important theory that may serve providers, investigators, 
administrators, researchers, and change agents well.  
  Evidence-based practice dissemination and implementation efforts should concentrate on 
the attitudes of the providers and certain practice viewpoints. The expansion of knowledge 
depends not only on adaptive practices, but also on fostering positive physician attitudes, and 
having the knowledge about an organization that encourages communication and change. 
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Rogers’ Diffusion of Innovations Theory Literature Review 
 Rogers’ Diffusion of Innovations theory has been included by various disciplines from 
huge conglomerates to small private practices. A systematic review by Greenhalgh, Robert, 
Macfarlane, Bate, & Kyriakidou (2004) discusses the Diffusion of Innovations theory concerning 
the healthcare service area and additional service organizations. The authors identified 13 
research areas that support the use of the Diffusion of Innovations in health service 
organizations. The authors found three main focal points: (1) an economical and evidence-based 
model regarding the Diffusion of Innovations in health service organizations; (2) a need to focus 
on further research on the Diffusion of Innovations in service organizations; and (3) a vigorous 
and convenient method for systematically reviewing multifaceted research evidence. 
 A study by Hader et al. (2007) focused on the views of physicians in utilizing clinical 
practice guidelines (CPG). The aim of this study was to evaluate why physicians did or did not 
employ innovations such as guidelines and to observe the degree to which these reasons fit a 
universal model of the innovation method. Forty-five physicians were interviewed regarding 
their opinions, attitudes, and behaviors towards CPGs for this qualitative study. The results of the 
study showed numerous major influences that the physicians saw as a necessity for them to adopt 
the innovations: (1) the physicians need to know that the guidelines exist; (2) the need for change 
must be apparent; (3) the need to know that the innovation has positive results and has no risk for 
their patients; (4) the patients and their families want the change; and (5) everyone involved 
supports the CPG and the physicians see positive patient outcomes with no augmented risk for 
continuation of the use of the CPG.  While CPGs are developed to improve the health of patients, 
the physicians were critical of CPGs and reluctant to adopt the CPGs if they believed the health 
of their patients might be at risk. Strengths of the study were not mentioned, neither were any 
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weaknesses. One weakness of the study however, is that it is a qualitative study and not 
generalizable.   
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Chapter II: Literature Review and Synthesis 
Search Strategy 
  Clinical practice guidelines and articles were searched from the following sites: National 
Guideline Clearinghouse, Science Direct, Cochrane Library, and Academic Search Complete, 
Cumulative Index to Nursing and Allied Health Literature (CINAHL), and PubMed. The 
following limits were set to include: articles published between 2005 and 2011, full text, in 
English, human subjects, randomized controlled trials (RCTs), and published in peer-reviewed 
journals. The search began with the keyword “ED” which yielded 9661 results. The addition of 
“erectile function” yielded 6738 results. Then adding “International Index of Erectile Function 
(IIEF-5)” narrowed the search to 1387 results. With the inclusion of the terms “diagnosis” and 
“treatment” the results were narrowed to 696. Again, the addition of the keywords “screening”, 
“evaluation”, “practice change”, “clinical setting”, and “provider behavior change” yielded 81 
results. The author individually reviewed each of these 81 articles and retained only those 
relevant to this project. A hand search or “snowballing technique” was utilized which produced 
three more relevant clinical practice guidelines. Articles were excluded if they did not contain 
the key terms: ED, diagnosis, treatment, and IIEF-5 together in the study. A total of 15 relevant 
articles including: five clinical practice guidelines (CPGs) (Canadian Guidelines Towards 
Optimized Practice [TOP], 2010; Hatzimouratidis et al., 2010; Kimoto et al., 2008; Montague et 
al., 2009; Qaseem et al., 2009), four systematic reviews (Cappelleri & Rosen, 2005; Markou, 
Perimenis, Gyftopoulos, Athanasopoulos, & Barbalias, 2004; Ruiz-Aragon, Marquez-Pelaez, & 
Romero, 2010; Tsertsvadze et al., 2009), three RCTs (Azuri, Gelerenter, Dushinat, Friedman, & 
Kokia, 2009; Hwang et al., 2010; Shabsigh et al., 2010), two prospective cohort studies (Hakim 
 17 
et al., 2002; Ponholzer et al., 2005), and one non-experimental descriptive study (Baldwin, 
Ginsberg, & Harkaway, 2003) were reviewed.  
Review of Literature 
A critical appraisal was completed on each of the 15 documents using the appropriate 
appraisal tool (Scottish Intercollegiate Guidelines, 2007; Appraisal of Guidelines Research & 
Evaluation Research Trust, 2006). The Canadian Towards Optimized Practice (TOP, 2010) 
program guideline focused on the management of ED in men. The TOP program ED clinical 
practice guideline (CPG) is a systematically produced publication and guideline established on 
evidence from scientific publications and medical journal articles. The guideline is meant to 
assist practitioner and patient decisions about healthcare for ED. To confirm clinical accuracy, 
the CPG is reviewed and validated regularly. The guideline was developed in 2001, reviewed in 
2004, and revised in 2006 and 2010. To produce and revise the CPG, the Canadian TOP’s 
Informed Practice team regularly reviewed the abridged publications of American College of 
Physicians (ACP) Journal Club, Evidence Based Medicine Journal, and Patient-Oriented 
Evidence that Matters (InfoPOEMS). These reviews examined a large base of the medical 
literature on ED, and the team used a systematic approach in choosing the most pertinent and the 
highest quality research. In addition, the condensed reviews were augmented with regular 
reviews of major journals, such as the British Medical Journal (BMJ), New England Journal of 
Medicine (NEJM), and The Journal of the American Medical Association (JAMA). 
Comprehensive searches of the published literature were performed on areas of significance, 
searching for the highest level of evidence (systematic reviews and randomized controlled trials). 
The Canadian Alberta (TOP) program funded the guideline. The goal of the guideline is plainly 
stated and represented early in the citations of the guideline. The target population and target 
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users of the guideline are well documented. Common causes, management, and available 
treatment options are well depicted. Moreover, documentation includes updating of the 
guideline. The authors do not mention whether any of the developers of the guideline were 
compensated for their contribution or list any conflicts of interest among the developing team. In 
the guideline, there was evidence that supported the use of a validated questionnaire for the 
diagnostic assessment of ED, along with physical examination and treatment options including: 
lifestyle changes, recommendations for initiating treatment with follow-up visits to evaluate 
progress and monitor therapy, and indications for referral. The guideline supported that the use 
of the Sexual Health Inventory for Men (SHIM) or IIEF-5 may be helpful in the clinical setting. 
Limitations associated with the guideline include the level/strength of evidence on which the 
guideline was established, how the guideline relates with the scientific evidence, and the 
potential cost of applying the recommendations. In addition, the developers do not specify 
whether the guideline was subjected to peer review and/or testing. 
The European Association of Urology (EAU) guideline focused on the epidemiology, 
diagnosis and treatment of ED and premature ejaculation (PE) in men (Hatzimouratidis et al., 
2010). The revision included an update on ED and as PE was a new addition to the guidelines, 
the authors included an evaluation of the highest quality scientific data, current research, and 
clinical practice, while taking their patient’s personal situations, principles, and preferences into 
account. The EAU provided the funding for the development of the guideline.  
In this guideline, the panel recommends the clinical use of a validated questionnaire for 
the diagnostic assessment of ED along with physical examination and treatment options 
including lifestyle changes, recommendations for initiating treatment with follow-up visits to 
evaluate progress and monitor therapy, and indications for referral. The goal of the guideline was 
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plainly stated and was represented early in the citations of the guideline. The developers 
conducted a systematic review of the literature in 2010 and seven revisions of the guideline from 
2000 to 2009. The target patient population and target users of the guideline are well published. 
Common causes, management, and available treatment options are well depicted. Each of the 
recommendations in the guideline is clear, easy to follow and has a level and grade of evidence 
upon which the guideline is established and associated with the scientific evidence. The 
recommendations made are clinically relevant, practical, with measureable outcomes, that if 
followed will aid in appropriate care for patients with ED. The guideline has been peer reviewed 
and tested. The authors mention that none of the developers of the guideline were compensated 
for their contribution nor was there any conflict of interest listed. Limitations associated with the 
guideline include the shortage of data concerning the probable cost of utilizing the 
recommendations. In addition, although the authors mention the IIEF-5 numerous times, the 
IIEF-5 tool was not included in the guideline. Furthermore, the authors do not specifically 
mention suitable criteria for screening and review purposes.  
The American Urological Association (AUA) Practice Guidelines Committee appointed 
an ED Guideline Update Panel (the Panel) in 2000 to update the existing guideline (Montague et 
al., 2009). The Panel’s key focus was to use an evidence-based style to create a guideline for the 
new ED treatment modalities, which had become available in the United States after the 1996 
Report was published. In addition, the Panel was to amend those sections that needed revising so 
that patients and physicians could have scientifically based information upon which to base their 
treatment and practice. There was strong evidence throughout the document that supported using 
the IIEF-5 as an outcome measure. The guideline objectives and clinical questions were plainly 
stated and clearly depicted early in the documentation. Databases utilized in the literature search 
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were clearly defined including several MEDLINE searches, with techniques that varied from 
very broad to very explicit. The systematic approach for evidence search was apparent and 
clearly documented with a sound relationship between recommendations and supporting 
evidence.  
The authors specify and document the potential users and the potential patient population 
for whom the guideline was intended. Relevant treatment options and their associated risks and 
benefits along with side effects of the treatment options were well explained. In addition, the 
Panel also outlined proposals for future clinical research issues. The guideline supports use of the 
IIEF-5 questionnaire, which was designed to be utilized in the clinical setting. The guideline was 
outlined, evaluated by the Panel and by 80 peer reviewers, and ultimately accepted by the 
Practice Guidelines Committee and the Board of Directors of the AUA. The AUA guideline is 
not funded by business in any way; the association finances all costs related to guideline 
development. If appropriate, the AUA may collaborate with other institutes to develop 
guidelines. This organization can offer additional funding for guideline development and present 
a probable conduit to increase distribution of the guideline. All panel members were volunteers, 
and therefore, compensation was to further the field of urology. The AUA acknowledges that full 
involvement on a guideline panel is an educational endeavor; consequently, panel members were 
granted up to 15 Continuing Medical Education (CME) credits at the conclusion of the guideline. 
Limitations associated with the guideline include the shortage of data concerning the probable 
cost of utilizing the recommendations. Also noted in the literature was the inconsistency in the 
use of standardized outcome measures for ED. According to the literature, there were 354 
different outcome measures (excluding the IIEF-5 tool) found. Additionally, the 15 questions of 
the IIEF-5 are divided into five domains and an overall score, however, questions 3 and 4 were 
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the most commonly reported while some studies reported using other domains and using 
multiple domains together.  
The Japanese Society for Sexual Medicine (JSSM) introduced a guideline for ED 
concerning the diagnosis and treatment of ED appropriate for general physicians (Kimoto et al., 
2008). The target readership in this case comprises most urologists whose practice does not 
concentrate on sexual dysfunction. Strong points of this clinical practice guideline consist of a 
well-depicted clinical question and solid documentation of systematic methods used to search for 
evidence. Funding for the guideline came exclusively from the JSSM with authorization of the 
Board of Directors. The authors conducted a literature search of PubMed as well as several 
specialty urology journals. The guideline was peer reviewed with levels of evidence cited in the 
guidelines and the recommendations graded. All of the members of the guideline preparation 
committee have received payments from various pharmaceutical companies during the past three 
years.  
The guideline supports the use of the International Index of Erectile Function 5 (IIEF-5) 
tool and maintains that it is helpful in the clinic. The guideline also includes ED diagnostic and 
treatment flow charts. Limitations include patients’ concerns or even involving the patients in the 
discussion for developing the guidelines were not included. In addition, the potential cost of the 
various treatment options was not addressed in the guideline.  
A clinical practice guideline from the American College of Physicians (ACP) (Qaseem et 
al., 2009) focused on presenting the available evidence on the hormonal testing and 
pharmacologic management of ED. In this guideline, 130 RCTs demonstrated significant 
evidence for the clinical benefits with the use of phosphodiesterase-5 (PDE-5) for treatment of 
ED regardless of the cause (such as mental illness, diabetes, or prostate cancer) or baseline 
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seriousness of ED. The 15 RCTs supporting the efficacy of hormonal blood tests in 
distinguishing and influencing therapeutic outcomes for treatable causes of ED was inconclusive. 
The target audience for this guideline is all physicians, and the target population is all males with 
ED. The guideline objectives and clinical questions were plainly stated and depicted early in the 
guideline. In addition, documentation was included that discussed the method for updating the 
guideline and conflicts of interest among the developing authors. Funding for the guideline 
development was obtained solely from the ACP.  
The systematic approach for evidence search was clear and well documented at the 
beginning of the guideline. Databases utilized for the literature search were acknowledged and 
included MEDLINE, AMBASE, Cochrane Central Register of Controlled Trials, and other 
databases. The guideline graded the evidence and recommendations utilizing the ACP clinical 
practice guidelines grading system. Various treatment modalities were described in the guideline 
along with their health benefits and side effects. Limitations include the patients’ concerns or 
even involving the patients in the discussion for developing the guidelines were not included. In 
addition, the potential cost of the various treatment options was not addressed in the guideline. 
Furthermore, there was no mention of using a measurement tool of any type for the diagnostic 
assessment of ED. Another limitation mentioned in the guideline was that the quality of the 
studies needed improvement. Still another limitation mentioned was that the evidence concerning 
the occurrence of adverse events was inadequate and questionable, and more high-quality head-
to-head trials are required to investigate disparities in adverse events.  
Cappelleri and Rosen (2005) conducted a systematic review of 21 studies on the 
prevalence of ED, 23 intervention studies on the efficacy of ED, and eight other studies (mostly 
correlational). There were three main objectives of the study: (1) to provide a status report on the 
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SHIM and its effect on the management of ED, (2) to provide a comprehensive account of 
studies in which the SHIM was utilized, and (3) to provide a systematic framework to manage 
and evaluate the studies. The results of the study concluded that the magnitude of research and 
quality of studies on the SHIM give evidence to the questionnaire’s positive effect on 
understanding and improving ED, and that this positive effect may remain significant in coming 
years. A sample size of 69,872 men from 52 studies was included in the review. A report on the 
methodology was clearly represented and thoroughly reviewed. The MEDLINE search of 
literature was meticulous and included pertinent, well-described studies that were comparable in 
style. The review incorporated studies that included prevalence, interventions, relationships, and 
that found the SHIM to be an integral measure of ED. Researchers and participants found the 
SHIM to be user-friendly, fast, economical, and simple to administer. Limitations of the study 
were: (1) some men answering the SHIM had not engaged in sexual activity either by choice or 
lack or opportunity, (2) there was some confusion between the elements of the SHIM and the 
full-scale IIEF or its Erectile Function (EF) domain, (3) there were slight problems that existed 
regarding the validation of the SHIM, and (4) the SHIM (IIEF-5) was not intended to diagnose 
the etiology of ED only the incidence and severity, as well as monitoring patient success with 
treatment.  
Markou and colleagues (2004) conducted a systematic review and meta-analysis of ten 
randomized controlled trials to determine the efficacy and safety of vardenafil in the treatment of 
male ED. The results of the study concluded that vardenafil increased the EF domain of the IIEF-
5 questionnaire by 6.18 units of weighted mean difference (WMD). Vardenafil also increased the 
percentage of erections firm enough to allow vaginal penetration (WMD: 26) and the percentage 
of sexual attempts that were successful per participant (WMD: 29.8). In conclusion, after a 12-
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week period of treatment, the evidence showed that in the general population of men with ED, 
vardenafil safely and without fail improved all efficacy facets of EF, enhancing erections and 
contentment in men.  
An account of the systematic methodology was plainly stated and thoroughly covered 
with detailed information on inclusion and exclusion criteria. A rigorous literature search was 
completed and included MEDLINE, Embase, CINAHL, Cochrane Library electronic databases 
and Current Contents. A manual search of the literature was performed, along with the European 
Agency for the appraisal of Medical Products and the records of the United States Food and 
Drug Administration advisory panel associated with pertinent approval applications. Included in 
the study were ten randomized controlled trials involving 6,809 men. Limitation of the study 
included heterogeneity (P<0.00001) of outcomes of the two primary and one secondary result. 
When reviewed, this seemed to have been clinical in origin because the population 
characteristics of the studies (diabetics, healthy participants, broad population, and radical 
prostatectomy patients) may have influenced the response.  
Ruiz-Aragon, Marquez-Pelaez and Romero (2010) conducted a systematic review of 10 
observational studies and 29 case series studies. The objective of the systematic review was to 
assess the erectile function in participants with a diagnosis of prostate cancer who planned to 
have surgery by one of three methods including laparoscopic, radical, or robotic prostatectomies. 
The results of the study concluded that there was a lower percentage of ED after the intervention 
in the participants who underwent robotic surgery (3-51%). Laparoscopic and radical surgeries 
showed higher percentages of impotence (36-91%). In looking at the case series, there appeared 
to be lower percentages of ED in participants who underwent robotic surgery (22%) then 
laparoscopic surgery (40%) and finally open radical prostatectomy (41.4%).     
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Recognized strengths of the study included an appropriate and clearly focused question. 
An explanation of the methodology was clearly illustrated and appropriately covered. The 
literature search was meticulous and incorporated significant, well depicted studies that were 
comparable in nature. Databases searches included: MEDLINE, Embase, Hayes, Cochrane 
Library, Center for Review Dissemination, and ECRI as well as databases of the healthcare 
technology agencies. The authors also conducted a manual search in journals specializing in 
cancer, urology, and prostate issues. A limitation of the study was the low quality of the reports 
used in the study. Additionally, since scientific publications were identified in the literature 
searches, a publication bias cannot be ruled out. Furthermore, there were no randomized 
controlled trials or high quality studies in the systematic review. In both the observational and 
the case series, heterogeneity was the major bias. This occurred mainly in terms of participant 
selection, procedures completed, and the fact that the observational studies were often different.  
Tsertsvadze et al. (2009) conducted a systematic review and meta-analysis of 222 
randomized controlled trials (RCTs) of oral phosphodiesterase-5 inhibitors (PDE-5) and 
observational studies of hormonal treatments for ED in a sample of 17,468 men. The results of 
the review showed that the PDE-5 inhibitors were more effective than placebo in improving 
sexual intercourse (69% versus 35%). In four RCTs comparing the three different PDE-5 
inhibitors, the adverse events were equal. Results from 15 of the RCTs evaluating hormonal 
treatment were inconsistent.  
A detailed description of the methodology was included, clearly described, and 
thoroughly covered. The literature search was thorough and included pertinent, well-described 
studies that were alike in nature. Databases for the literature search included: MEDLINE, 
EMBASE, Cochrane Central Register of Controlled Trials, PsycINFO, AMED, and SCOPUS. 
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Included studies were evaluated for strength of evidence by using the appropriate methods and 
judged using accepted criteria and review protocols. The strength of the study was the large 
amount of high-grade evidence on therapeutic effects of PDE-5 inhibitors compared with 
placebos for men with ED. A limitation of the study was that numerous trials were received with 
limited methodological and reporting quality, predominantly those that directly compared PDE-5 
inhibitors, and those that assessed hormonal therapies. Additionally, clinical or methodological 
heterogeneity and nonexistent information narrowed the amount of statistical data pooling. 
Furthermore, according to the authors, the small number and selective coverage of serious 
cardiovascular events were conflicting and incomplete and should be explained with concern. In 
addition, most of the RCTs presented only short-term efficacy and harms data and longer-term 
data was unavailable.  
Hwang et al. (2010) conducted a randomized controlled trial with a second randomized 
booster to present current data on the prevalence of ED in Taiwanese men and to validate the 
erection hardness score (EHS) and Quality of Erection Questionnaire (QEQ) in this population. 
The results of the study concluded that the prevalence of ED, as defined by IIEF-5, was 27% 
among all participants and 29% among those 40 years of age or older. While prevalence of ED 
increased with age, men of all ages had a propensity to underestimate their ED. By utilizing the 
IIEF-5, the authors found that 25% of the men who identified that they did not have ED, in 
reality, had mild to moderate ED. The authors used the IIEF-5 as a comparison tool to validate 
the EHS and the QEQ for the assessment of ED.  
Strengths associated with this study include the randomized controlled trial study design 
with the second randomized booster. Study methods were well detailed with information on 
inclusion and exclusion criteria. There were 1,009 men eligible to participate in the study during 
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the first randomization and the second random booster included another 51 men. A limitation of 
the study was the use of a telephone interview one time only to validate the EHS. In the 
telephone interview, numerous calls were necessary to make just one contact, privacy may have 
been inadequate, and participants who had health problems such as a knowledge deficit or 
hearing issues may have been at a disadvantage with this kind of survey.  
Shabsigh et al. (2010) conducted a double blind randomized, placebo-controlled trial 
using a sildenafil flexible dose to identify previously unrecognized or undiagnosed ED so that it 
could be discussed as a medical condition. The prevalence of unrecognized ED with 
comorbidities commonly associated with ED was determined by analyzing the results of the 
study. Men eligible for the study were > 30 years old with at least one risk factor. Risk factors 
include but were not limited to: smoking, cardiovascular disease, diabetes, controlled 
hypertension, metabolic syndrome, obesity, and depression, as well as no past or current 
diagnosis of ED.  Conversely, men with these conditions may also have underlying ED.  Criteria 
for admission into the study also included the use of the EF domain of the IIEF questionnaire. 
The EF question asks the participant whether or not they currently have ED. The participants that 
answered with a “no” or “unsure” were eligible for inclusion into the study. 
In this study, 1,053 men responded to the Erection Function domain of the IIIEF-5-EF 
questionnaire and received a score. In general, IIEF-5-EF diagnosis of ED were documented in 
71% (744/1053) of males, of which 54% (399/744) had moderate or severe ED (IIEF-5-EF score 
< 16), 23% (171/744) had mild-to-moderate ED (IIEF-5-EF score 17-21), and 23% (174/744) 
had mild ED (IIEF-5-EF score 22-25). A limitation of the trial design was that the basis for 
men’s explicit answers to the screening question was not investigated further. The authors found 
that while awareness of having ED was minimal, most of the participants with risk factors had a 
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IIEF-EF score indicating some degree of ED and recommend that patients with risk factors be 
evaluated. 
Azuri, Gelerenter, Dushinat, Friedman, and Kokia (2009) used a randomized controlled 
trial to examine the outcome of increasing understanding of the diagnosis and treatment of ED in 
a community environment using physicians’ education. A sample size of 1,959 men in two 
intervention groups and 1,903 men in the control group along with a random sample of 40 
primary care physicians in both the intervention and control groups were the focus of this study. 
The results of the study showed that during the six-month timeframe prior to the intervention and 
the six-month timeframe after the implementation, there were no major differences in diagnosis 
of new ED participants, in PDE-5 inhibitor prescriptions or in referrals to urologists. The 
findings lead the authors to determine that periodic lectures and electronic patient records do not 
significantly influence the physician’s actions. Limitations of the study included: (1) participants 
may not have had ED, even though they were chronic patients with long-standing risks, (2) 
participants may not have seen their provider during the six-month follow up timeframe, and (3) 
an extended follow up timeframe may improve the chances of diagnosis and treatment. 
Furthermore, even though the authors followed more than 3,000 patients, the study sample (20 
physicians and 20 physician controls) was small. 
A prospective study by Ponholzer et al. (2005) focused on examining erectile function 
with a validated study instrument in 2,869 men between the ages of 20 and 80 years with 
numerous possible risk factors taking part in a health investigation in a municipal area of Vienna. 
The objective of this study was to evaluate incidence and risk factors for ED by examining a 
large group of men taking part in a health investigation and by using the IIEF-5. As evidenced by 
the IIEF-5 score, 32.2% had no ED (IIEF-5 score greater than 22), 23.7% had mild ED (IIEF-5 
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score 17 to 21), 5.0% mild to moderate ED (IIEF-5 score 12 to 16), 2.2% moderate ED (IIEF-5 
score 8 to 11) and 1.3% severe ED (IIEF-5 score 0 to 7). Risk factors for ED increased with age, 
diabetes, hyperlipidemia, lower urinary tract symptoms, hypertension, psychological stress, and 
low physical activity (all, p < 0.05).  
Strengths of the study included the fact that all participants completed a thorough health 
examination with standardized assessment of medical history, physical examination, and a 
laboratory study. In addition, the authors used the IIEF-5 to measure prevalence and seriousness 
of ED. Furthermore, due to recruiting men participating in a health screening, the study had a 
good sample size with 2,869 participants. Limitations included that a sample bias could not be 
excluded, as the typical epidemiological model was not used to generate the study population. In 
addition, the majority of males over 60 years of age in Austria is retired and has more time for 
physical activity, which may cause selection bias in this age group. 
A prospective study by Hakim, Subit, Kandzari and Zaslau (2002) appraised the 
screening patterns of primary care physicians with respect to ED. The study was conducted 
utilizing the SHIM questionnaire with men that came to a urology clinic. The study included 102 
male patients that completed and returned the survey. Of the patients returning the SHIM 
questionnaire, 56% had a score of 21 or less, diagnostic of a degree of ED. Eighty-three percent 
had primary care physicians (PCP); 23% of participants with a PCP were screened for ED and of 
those, 58% initiated the discussion with their physician. The results of the study also 
demonstrated that participants leave the PCPs office without being screened for ED. This study 
found that a validated questionnaire such as the SHIM should be utilized with participants who 
have any identifiable risk factor. In addition, monitoring for ED is appropriate, as effective 
treatment of ED is obtainable. It was also noted that ED could be linked with undiagnosed 
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cardiac disease. Limitations of the study included the predominant use of elderly participants. In 
addition, selection bias may have occurred as participants included only those with ED. 
Furthermore, the small sample size of 102 participants was a limitation of the study. 
A non-experimental descriptive study by Baldwin, Ginsberg, and Harkaway (2003) 
assessed the under-reporting of ED among men with unrelated urologic issues. The aim of this 
study was to evaluate the occurrence of ED in men with unconnected urologic conditions and 
sought the rationale for why the men did not always report ED. There were 500 men enrolled in 
this non-experimental descriptive study. The results of the study suggested that the majority of 
men (82%) with some degree of ED who had not reported ED wished that the primary care 
physician had brought the topic up during a regular office visit. In addition, 74% of those 
suffering some degree of ED were self-conscious, and as a result, did not want to discuss ED 
with the urologist. The study also found that urologist had to ask specific questions to get the 
patients to discuss ED, while patients seemed at ease and ready to talk about ED with the 
primary-care physicians. The most common reason cited for the under-reporting of ED was 
embarrassment. The strength of the study was the availability of men in the urology clinic. A 
limitation to the study was that the patients were already seeing an urologist.  
Synthesis 
The evidence collected through the appraisal of 15 documents including: four clinical 
practice guidelines (Canadian Guidelines Towards Optimized Practice [TOP], 2010; 
Hatzimouratidis et al., 2010; Kimoto et al., 2008; Montague et al., 2009), four systematic reviews 
(Cappelleri & Rosen, 2005; Markou et al., 2004; Ruiz-Aragon et al. 2010; Tsertsvadze et al., 
2009), two RCTs (Hwang et al., 2010; Shabsigh et al., 2010), and two prospective studies 
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(Hakim et al., 2002; Ponholzer et al., 2005) support the use of a validated questionnaire for the 
diagnostic assessment of ED.  
Evidence from all five clinical practice guidelines (Canadian Guidelines Towards 
Optimized Practice [TOP], 2010; Hatzimouratidis et al., 2010; Kimoto et al., 2008; Montague et 
al., 2009; Qaseem et al., 2009), two systematic reviews (Markou et al., 2004; Tsertsvadze et al., 
2009) and one RCT (Azuri et al., 2009) supports the use of the PDE-5 inhibitors for the 
treatment of ED, with the five clinical practice guidelines (Canadian Guidelines Towards 
Optimized Practice [TOP], 2010; Hatzimouratidis et al., 2010; Kimoto et al., 2008; Montague et 
al., 2009; Qaseem et al., 2009) supporting PDE-5 inhibitors as first line therapy.  
Supported by the collective results of these studies, a validated questionnaire does 
promote ease of discussion and facilitates diagnostic assessment of ED in the clinic. 
Furthermore, PDE-5 inhibitors were supported as first line treatment for ED. Heterogeneity was 
found across some of the studies. Ruiz-Aragon et al. (2010) emphasized that in both 
observational studies and case series the major bias observed was heterogeneity, largely in 
relation to patient choice, procedures executed, and ways of comparing observational studies, 
which were not always alike. Markou et al. (2004) stated that the heterogeneity of outcomes 
between using vardenafil or placebo of the two primary and one secondary result when reviewed 
gave an impression of being clinical in origin, since the population traits of the study (diabetes, 
general patient population, healthy patients, and surgical patients, such as prostatectomy patients) 
may influence the results. The differences in the sample characteristics could cause discrepancies 
in outcomes across studies.  
Gaps exist in the evidence about treatment specific agents and long-term consistency of 
the PDE-5 inhibitors over time. While four (Canadian Guidelines Towards Optimized Practice 
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[TOP], 2010; Hatzimouratidis et al., 2010; Kimoto et al., 2008; Montague et al., 2009) of the 
clinical practice guidelines support the use of a validated questionnaire, they may need to be 
upgraded to specify one in particular and make the use of the questionnaire a recommendation. 
The majority of the studies reviewed provide strong evidence to support the use of a validated 
questionnaire in the clinic for the diagnostic assessment of ED and the use of the PDE-5 
inhibitors as a treatment option for ED. Support of the need for a protocol change is included in 
the body of evidence, which includes the utilization of a validated questionnaire that assists in 
changing provider behavior, and improves provider observance of the suggestions in the clinical 
guidelines for ED. Based on the review of the literature the following PICO question was 
developed:  Does provider education and the use of the International Index of Erectile Function – 
5 (IIEF-5) questionnaire increase diagnosis of ED and documentation of treatment options in two 
clinics in Southern West Virginia?  
Project’s Congruence of Organizations Strategic Plan  
 The settings for this pilot project were two private practice primary care clinics in 
southern West Virginia.  This pilot practice change was supported by the missions of both 
clinics. The overall mission of both clinics is to provide quality professional healthcare, to 
promote health, prevent illness, and to empower patients to manage their health. Both clinics are 
dedicated to improving the quality of health care and health outcomes through providing timely, 
innovative, and compassionate care. Chronic medical conditions found at both clinics include: 
Types 1 diabetes, Type 2 diabetes, hypertension, cardiovascular disease, psychological problems, 
hyperlipidemia, obesity, smoking, and alcohol abuse. The main goal of the pilot project was to 
evaluate the incorporation of the IIEF-5 questionnaire into the patient’s chart to increase the 
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diagnosis and documentation of treatment options for ED when indicated by the score on the 
questionnaire. The main goal of the pilot project and the goals of the clinics are congruent. 
Project 
 This pilot project was comprised of an educational session on the use and scoring of the 
IIEF-5 questionnaire followed by an evaluation of provider behavior change in the assessment, 
detection, and documentation of treatment options for patients with ED. The IIEF-5 
questionnaire was utilized in two clinics in southern West Virginia over a six-week period. 
Information and education on ED and the use of the IIEF-5 questionnaire was given to both 
providers separately during a single meeting prior to the implementation. The investigator 
completed a pre implementation (n=50) random chart review and a post implementation chart 
audit on the (n=89) completed questionnaires to evaluate the use of the questionnaire in 
assessing, detecting, and documenting plans of care and follow-up for patients with ED. The 
proposed pilot project was completed with delivery of outcomes to the stakeholders.  
Goals and Objectives 
The main goal of the project was to evaluate a pilot project to incorporate the IIEF-5 
questionnaire into the patient’s chart, to increase the diagnosis and documentation of treatment 
options for ED as indicated by the score on the questionnaire. This innovation was implemented 
to improve the health status of the patient population. Understanding the significance of ED has 
augmented the importance of early detection and increased quality of life.  The hypotheses for 
the capstone project are: a) the use of the IIEF-5 questionnaire in the clinical practice will 
increase the diagnosis of ED; b) the use of the IIEF-5 questionnaire in the clinical setting will 
increase the documentation of the discussion of treatment options for men with ED when 
indicated by their score.   
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Subsequently, the five objectives for this capstone project were: 
1. To increase provider awareness relating to the use of the IIEF-5 questionnaire for ED. 
2. To increase the number of patients who are screened for ED. 
3. To increase the number of patients with a diagnosis of ED. 
4. To increase the number of patients diagnosed with ED receiving treatment options as 
documented in the charts. 
5. To increase the number of patient charts with documentation of ED. 
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Chapter III: Methodology 
Project Design 
 This pilot project was submitted to the West Virginia University Institutional Review 
Board (IRB). It was reviewed by the IRB, approved, and determined to be expedited. The project 
used a descriptive design to address the objectives.  
 This capstone project was designed to incorporate the use of the IIEF-5 questionnaire into 
the patient’s chart to increase the diagnosis and documentation of treatment options for ED when 
indicated by the score on the questionnaire (Appendix A). The providers at both clinics granted 
permission to include the use of the IIEF-5 questionnaire into their perspective clinic 
(Appendices B & C). The capstone project was designed based upon national guidelines and 
evidence-based research.   
The capstone project was conducted over a six-week period, with weekly phone 
discussions and bi-weekly visits to the sites to answer any questions and keep supplies of the 
questionnaires and pens on hand. The IIEF-5 questionnaire was given to all male patients 
between the ages of 40 to 70 years visiting the clinics during the six-week study period who 
agreed to participate in the study. Attached to the IIEF-5 questionnaire was a demographic sheet 
seeking information such as age, marital status, race, and co-morbidities such as diabetes, 
cardiovascular disease, hypertension, kidney disease, depression, etc. as found on the 
Demographics/Cover page (Appendix D). This capstone project also included a Data Collection 
Form for the providers to complete and scan into the patient’s chart, which served as a reminder 
during the patient’s next visit of the patient’s erectile function status (Appendix E).  This 
capstone project provided an IIEF-5 questionnaire for the providers to use to assist in the 
assessment, diagnosis, and discussion for treatment options of ED as identified by the patient’s 
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score.  According to the scoring of the IIEF-5, severity of ED is classified with the following 
scale: a score of 0-7 equates with severe ED, a score of 8-11 equates with moderate ED, a score 
of 12-16 equates with mild to moderate ED, a score of 17-21 equates with mild ED, and a score 
of 22-25 equates with normal/no ED (Table 1). 
Table 1 Assessment of ED – IIEF-5   
 
Normal Erectile Function Score  22 - 25 
Mild ED        Score      17 - 21 
Mild to Moderate ED      Score      12 - 16 
Moderate ED        Score         8 - 11 
Severe ED        Score         0 - 7  
 
 
The investigator discussed the use of the IIEF-5 questionnaire with the key stakeholders 
during a face-to-face one-on-one conversation with both clinic providers to evaluate the 
probability of the proposed pilot project.  
Resources 
To complete the pilot practice project, the following resources were required: providers 
or key stakeholders, IIEF-5 questionnaires with permission to use, educational materials, 
demographics/cover sheet tool, data collection tool, timeline for the project, and a budget plan. 
The primary resource for championing implementation of the pilot project was the providers or 
key stakeholders at each clinic. Involvement in this pilot project did not alter the day to day 
duties of normal patient care. The investigator discussed each phase of the pilot project with the 
providers prior to its design in order to elicit their input and gain their acceptance of the pilot 
project.  
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 Other resources necessary to implement the pilot project included items such as copies of 
the questionnaire (Appendix A), the pre-numbered log sheet (Appendix H), the 
demographics/cover page (Appendix D), pens, and gasoline for trips to the sites. The investigator 
compiled and presented an educational program (Appendix J) to the providers at both clinics.  
Procedure 
Instruction in the use and scoring of the IIEF-5 was necessary as neither provider had 
heard of the questionnaire.  A formal teaching session was held with both providers individually 
during after clinical hours to explain the questionnaire and how to score the tool. One of the 
objectives of the pilot project was to improve provider awareness relating to the use of the IIEF-5 
questionnaire for ED.  The instructional focus incorporated (a) the use of the IIEF-5 
questionnaire in the clinical practice, (b) scoring the completed questionnaire, (c) patient 
population to be included in the pilot project, (d) importance of follow-up with patients whose 
score were indicative of diagnosis of ED, (e) the documentation of erective dysfunction into the 
patients charts, and (f) treatment options offered to the patients.  
Evidence from research studies and ED guidelines were discussed with the providers in 
hopes of garnering their support for the pilot project. Each of the providers discussed the pilot 
project with their respective nurse and decided what part the nurse would take in the pilot 
project. The nurses at both clinics gave the pre-numbered questionnaire to the patients who 
agreed to participate after writing the patient’s name on the corresponding pre-numbered log 
sheet; the nurse scored the questionnaire and placed the questionnaire in the exam room with the 
patient.  The provider then discussed the score of the questionnaire with the patient during the 
patient’s visit.  The log sheet was kept in the provider’s possession at all times, when the 
investigator was not obtaining necessary information for the pilot project. Both clinics utilize an 
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electronic medical record (EMR) for patient charts and as such, the providers had the nurse scan 
the scored questionnaire into the patients’ chart.  
The provider completed the data collection form during the patient’s visit.  The data 
collected included patient questionnaire, IIEF-5 score, age, and whether the patient had a pre-
existing diagnosis of or was being treated for ED. The data collection tool (Appendix E) was 
used to collect specific objective data on measures supported by the guidelines. The tool was 
based on the American Urological Association guidelines (Montague et al., 2009) and supporting 
evidence from the literature with emphasis on risk factors and early detection of ED. In addition 
the Data Collection form also included areas for the provider to mark whether or not there was: 
follow-up appointments scheduled to evaluate treatment and whether or not the patient was 
satisfied with his current treatment (Appendix E). The providers kept the list identifying the 
patient name with the corresponding numbered questionnaire locked in their offices when they 
were not using the list. When the providers were using the list, either the providers or their nurse 
kept them at their workplace in the clinic at all times. Some of the charts did not hold all the 
information needed to fill out the tool; therefore, the investigator designed the Data Collection 
form to reflect this. Information not found in the charts, but included on the Data Collection form 
included: whether the patient had undergone specific laboratory test, whether the patient had a 
follow-up to evaluate treatment of ED once diagnosed, whether the patient was satisfied with his 
current treatment, etc. (Appendix E).  
Budget 
The investigator developed a budget plan to project and control cost of the pilot project 
(Appendix G).  The cost of space at the clinics, provider and staff participation and time, the use 
of the IIEF-5 questionnaire, and the nurse practitioners time were all donated. Other costs 
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included the investigator’s time to put together the questionnaires, educate the providers, travel 
expenses, office supplies, Christmas baskets in lieu of pre implementation lunch, and post pilot 
project disclosure lunches for the clinics. The total cost of the pilot project was $541.02, of 
which $500.00 was grant money. The most significant cost was that of the copies of the 
questionnaires for the clinics.   
Evidence of Key Site Support  
The sites for the implementation of the capstone project were two primary care clinics in 
southern West Virginia, at which the investigator had been in ongoing discussion since early 
2010, when the investigator was conducting a needs assessment. The practice owners were 
supportive of the investigator’s project. There had been multiple discussions between the clinic 
providers and the investigator regarding the project and the questionnaire, along with the 
potential benefits to the clinics and patient. Signed letters of support were obtained that allowed 
implementation of the pilot project at the sites (Appendices B, C). 
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Chapter IV: Results 
Characteristics of the Sample 
 
 The sample for this pilot project were patients of two primary care doctors in two clinics 
in southern West Virginia.  One of the medical providers is an Internal Medicine Doctor (MD) 
and female, while the other is a Family Practice Medical Doctor (MD) and male. This pilot 
project consisted of two samples: the baseline sample and the post implementation sample. 
Criteria for the randomly selected patients from the clinics were that of male patients, 40 to 70 
years of age, with or without an ICD-9 code of 607.84 and 302.72. The post implementation 
sample consisted of all male patient 40 – 70 years of age that completed the IIEF-5 questionnaire 
during their visit with the providers. The baseline sample (n=50) had a mean age of 53.1 with a 
standard deviation of 8.3 years, with the minimum age of 40 years and the maximum age was 70 
years. The number of male patient charts that were included in the post implementation pilot 
project was (n=71) and had a mean age of 59.7 years with a standard deviation of 6.6 years and 
included one patient with an unknown age (Table 2). In both the pre and post implementation 
sample race/ethnicity was 90.9% (n=110) Caucasian and 1.7% (n=2) African Americans, which 
is fairly consistent with the racial/ethnicity statistics of Raleigh and Kanawha Counties in West 
Virginia. Race/ethnicity was found to be unknown in 7.4% (n=9) of the total charts reviewed. 
Another factor in the pre/post combined data sets that was reviewed was marital status, which 
included a sample of 78.5% (n=95) married, 9.1% (n=11) divorced, 1.7% (n=2) unknown, 7.4% 
(n=9) single and 3.3% (n=4) are cohabitating (Table 2). 
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Table 2 Pre and Post Implementation Demographic Data 
Demographics Pre Implementation 
Chart review   
(n=50)  
n (%) 
Post Implementation 
Chart review   
(n=71)  
n (%) 
All patients    
(n=121)  
 
n (%) 
Age (years)    
40-50 years 23 (46) 5 (7) 28 (23) 
51-60 years 15 (30) 31 (44) 46 (38) 
61-70 years 
Unknown 
12 (24) 
0 
34 (68) 
1 
46 (38) 
1 
Mean (SD) 53 (8.3) 60 (7) 57 (9) 
Minimum-maximum 40-70 40-70 40-70 
Race, n (%)    
White 46 (92) 64 (90) 110 (90.0%) 
African American 1 (2)   1(1.4)    2 (1.7%) 
Asian 0 0 0 
Unknown 3 (6) 6 (8)     9 (7.4%) 
Marital Status    
Married 36 (72) 59 (83)   95 (78.5%) 
Divorced  5 (10) 6 (8) 11 (9.1%) 
Unknown 1 (2)    1 (1.4)   2 (1.7%) 
Single  6 (12) 3 (4)  9 (7.4%) 
Cohabitating 2  2  4 (3.3%) 
    
Note: The pre implementation sample was randomized, whereas the post implementation sample 
was a convenience sample. An Independent sample t-test was conducted to compare the age 
differences between the pre and post implementation groups.   
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Co-morbidities were addressed and collected on the Data Collection form (Table 3). 
Table 3 Pre and Post implementation Co-Morbidities 
Co-Morbidities Pre 
Implementation 
Chart review 
(n=50)  
n (%) 
Post 
Implementation 
Chart review  
(n=71)  
n (%) 
  Frequency  
Total Number 
of patients 
with 
Comorbidity 
 
 
Smoking/Tobacco 
 
23 (46) 
 
14 (20) 
 
37 (31) 
 
Alcohol 23 (46) 16 (23) 39 (32)  
Diabetes 9  (18) 22 (31) 31 (26)  
Heart Disease 7  (14) 23 (32) 30 (25)  
Hypertension 28 (56) 30 (41) 58 (48)  
Kidney Disease 2 (4) 5  (7) 7 (6)  
Peripheral Vascular 0 5  (7) 5 (4)  
Thyroid Problems 4 (8) 10 (14)  14 (12)  
Depression 22 (44) 12 (17) 34 (28)  
Decreased sex drive 0 21 (30) 21 (17)  
Prostate surgery 1 (2)             5  (7) 6 (5)  
Multiple sclerosis 0 0 0  
Current treatment of 
Nitrates 
 
1 (2) 
 
 1 (1.4) 
 
2 (2) 
 
Spina bifida 0              2  (3)  2  (2)  
Prostate problems 10 (2)  9  (13) 19 (16)  
Spinal cord injury   2 (4)   1  (1.4) 3  (2)  
Penile trauma 0 0   0  
Hyperlipidemia  22 (44) 3 (4) 25  (21)  
 
Project Results  
Provider objectives.  Informed consent forms from both providers were obtained prior to 
the start of the pilot project, as well as the investigator signing a HIPAA form at both clinics. 
Both providers articulated understanding of the proposed pilot project and their involvement in 
the pilot project.  
  The first objective was to increase provider awareness relating to the use of the IIEF-5 
questionnaire for ED as measured by utilization of the IIEF-5 in the clinic. This objective was 
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met when the investigator discussed and introduced the IIEF-5 questionnaire to the two primary 
care providers.  
The post implementation chart audit (n=71) revealed an increase in patient charts in that 
53 or 75% of the patients answering the questionnaire had a new documented diagnosis of ED. 
The providers voiced their satisfaction in the ease of using the questionnaire and the results they 
were seeing in their patient’s questionnaire scores. Chi-square analysis demonstrated a 
statistically significant rise in the total of patients diagnosed post implementation (p<0.00). Post 
implementation chart review showed 100% of the patients that received a diagnosis of ED had 
documentation of ED in their charts. 
Patient objectives. The second objective was to increase the number of patients who 
were screened for ED as measured at the beginning and at the termination of the pilot project by 
the number of IIEF-5 questionnaires that were completed. This objective was met in that there 
were 89/250 (36%) questionnaires completed, of which 71 (80%) were eligible for this pilot 
project. Patients with a current or previous diagnosis of ED or currently receiving treatment for 
ED, as well as those <40 or >70 years of age were excluded. 
Utilization of the IIEF-5 questionnaire by the providers in the clinic during the six-week 
pilot project provided evidence of an increase in identification of ED in patient’s charts.  Data 
gathered on the data collection form consisted of specific questions including: (a) was the IIEF-5 
questionnaire discussed with the patient (n=71): the providers discussed the questionnaire with 
71 patients, (b) was the patient’s score (n=71) discussed: the providers documented that the 
patient’s score was discussed with 71 patients (100%). 
The third objective was to increase the number of patients with a diagnosis of ED as 
measured using the IIEF-5 questionnaires. Beginning measurements during the pre 
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implementation period via chart review revealed five of 50 patients (10%) had a diagnosis of ED. 
Data utilizing the IIEF-5 questionnaire scores from the post implementation group assessment 
showed a diagnosis of ED in various degrees in (n=53/71) or 75% of the male patients 40 to 70 
years of age (Table 4). Chi-square analysis demonstrated a statistically significant rise in the total 
of patients diagnosed post implementation (p<0.00). 
Table 4 Pre and Post Implementation Diagnosis ED 
Diagnosis Pre Implementation 
(n=50)  
n (%) 
Post Implementation  
              (n=71)  
 n (%) 
Combined Total 
        (n=121) 
           n (%) 
 
Erectile Dysfunction 5 (10) 53 (75)          58 (48) 
 
Table 5 Pre and Post Implementation Diagnosis ED – Age 40 - 49 and 50 - 70 years 
Demographics 
 
Pre Implementation 
Chart review   (n=50) 
with ED 
n (%) 
Post Implementation 
Chart review   (n=70)  
with ED 
n (%) 
All Patients  
Chart review (n=120) 
 
n (%) 
Age (years)    
40-49 0/21(0) 3/4(75) 3/25(12) 
50-70 5/29(17) 50/66(76) 55/95(58) 
    
 
There were no significant differences in ages for males 50 to 70 years between the pre 
and post implementation group (0.6). However, there was a statistical significant difference 
between the pre and post implementation males < 49 years of age. In Group 1 – 21/50 (42 %) of 
the men were <49; Group 2 – 4/71(5.6%) were < 49 years. Prevalence of ED in Group 1 of 
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participants 50 - 70 years of age was 5/29 (17%), while prevalence of ED in Group 2 - 
participants 50 - 70 years of age was 50/66 (76%). There was one participant in the group with 
an unknown age. Chi-square analysis demonstrated a statistically significant rise in the total of 
patients diagnosed post implementation (p<0.00) (Table 5). 
According to the scoring on the IIEF-5, a patient score of less than 22 is indicative of a 
degree of ED. Severity and prevalence of ED via scoring on the IIEF-5 questionnaire for this 
pilot project is as follows: normal erectile function was 18/71(25.4%); mild ED was 16/71 
(22.5%); mild to moderate ED was 15/71 (21.1%) moderate ED was 6/71 (8.5%) and severe ED 
was 16/71 (22.5%) (Table 6). 
Table 6 Severity and Prevalence of ED 
 
Assessment              Post Chart Review (n=71)             %  
 
Normal Erectile Function                     18   25.4   
Mild ED 16 22.5   
Mild to Moderate ED 15 21.1   
Moderate ED   6 08.5 
Severe ED 16 22.5  
______________________________________________________________________________ 
The fourth objective was to increase the number of patients diagnosed with ED receiving 
treatment options as documented in the charts. Of the eligible 71 completed questionnaires, 
discussion of ED was found on 71(100%) of the patients charts. Patient scores were found in 71 
of the 71 (100%) completed questionnaires, with 53/71 having a score < 22, indicating a degree 
of ED. Success of the project was in large, due to the two primary care providers commitment to 
their patients. Both providers were willing to listen to the Project Leader’s presentation on ED, 
evidence-based practice, and the use of the IIEF-5 in the clinical setting.  Success of the project 
was also due to the Project Leader’s passion for wanting to assist patients with ED and her 
ability to promote how using this questionnaire could benefit not only the patient, the patient’s 
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interpersonal relationship, the potential benefits to the patient’s health, but the providers 
communication and rapport with the patients, as well as, the clinics bottom line.  
Utilizing a question on the data collection form: were treatment options offered to the 
patients whose scores indicated a degree of ED (n=53) resulted in 42 patients offered treatment 
(79%), 11 patients were not offered treatment (21%).  Of the 11 patients not offered treatment, 
five had heart disease, four scheduled follow-up visits to discuss options, one patient was not 
interested, and one admitted that he was not sexually active. On the pre implementation chart 
review 2/5 patients that had a documented diagnosis of ED had a documented treatment option 
(40%). Chi-square analysis demonstrated a statistically significant in the total of patients offered 
treatment for ED (p <0.00).  
The fifth objective was to increase the number of patient charts with documentation of 
ED. This was measured by the IIEF-5 questionnaire found scanned in the patients EMRs. There 
were 89 patients (100%) found to have a questionnaire scanned in their charts, whether or not the 
patients were eligible for the pilot project. Pre implementation chart review found five of 50 
patient charts with a documentation of ED, whereas post implementation found 53 of 71 
patient’s charts with a documented diagnosis of ED. 
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Chapter V: Summary, Discussion, Implications 
Congruence with Theoretical Framework 
 
This pilot project demonstrated congruence with Rogers’ Diffusion of Innovation 
theoretical framework.  Rogers defines innovation, the first of his four main elements of 
diffusion as: “An innovation is an idea, practice, or project that is perceived as new by an 
individual or other unit of adoption” (Rogers 2003, p.12). An innovation may not be new, as in 
the IIEF-5, but to the providers, the IIEF-5 questionnaire was new to them and their clinics, as 
neither had heard about the IIEF-5 prior to the investigator approaching them for permission to 
do the pilot project in their clinic, therefore their perception was that it is a new innovation. 
According to Rogers (2003) consequences are deviations that happen to an entity or a social 
system, as an outcome of the acceptance or dismissal of an innovation. The innovation for this 
pilot project involved a practice change to incorporate the IIEF-5 questionnaire into the clinics 
for diagnosis and documentation of treatment options offered in two clinics in southern West 
Virginia. The providers chose to accept this innovation and adopt it for their clinics. To diminish 
the ambiguity of accepting the innovation, entities should be well-versed about its benefits and 
weaknesses to make them cognizant of the consequences.  The providers found over the six-
week pilot project period, that the innovation to incorporate the IIEF-5 questionnaire into the 
clinics for diagnosis of ED was of great benefit to their patients. Moreover, the providers 
discovered that the addition of the IIEF-5 questionnaire into the patients EMR was worth the 
extra time, for accurate documentation of a diagnosis and discussion of ED as indicated by the 
score on the questionnaire, and of the treatment options offered. Communication is the second 
element and is the practice where the members generate and communicate evidence amongst the 
group to reach a collaborative understanding.  This communication transpires via channels amid 
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sources.  According to Rogers (2003), a source is an entity or an organization that creates a 
communication, whereas, a channel is the method by which a communication moves from the 
source to the beneficiary. Effectively communicating the new innovation to the providers or key 
stakeholders was vital to the success of this pilot project. Meeting one-on-one with the providers 
to inform them of what the pilot project entailed, their part in the pilot project, and answer any 
questions or concerns regarding the pilot project and following up with visits, phone calls, and 
educational materials helped to further ensure the success of the pilot project. The third element 
of the diffusion on innovation theory is time. A new innovation spreads across the social system 
over time. According to Rogers (2003) time is encompassed in diffusion in the innovation-
decision process, the innovativeness of an entity or other measure of adoption, and an 
innovation’s rate of adoption in a specified time period. Social system is the last element in the 
diffusion process. According to Rogers (2003) the social system is a group of interconnected 
components involved in shared problem solving to achieve a mutual goal. 
Discussion 
 The goal of this pilot project was to evaluate the effectiveness of the International Index 
of Erectile Function (IIEF-5) questionnaire on the diagnosis and treatment of ED in southern 
West Virginia. This pilot project was an initial evaluation of a practice change at both clinics. 
Both physicians were receptive to the pilot project and excited about the end results that there 
were no challenges or issues. Providers from both clinics voice satisfaction in the use of and the 
results of the pilot project and have determined that they will continue to use the questionnaire 
for their patients. This pilot project will function as the underpinning for future projects in both 
clinics. 
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 Utilization of the validated, internationally recognized IIEF-5 questionnaire in this pilot 
project gives evidence to the value of the tool in the clinic setting to measure prevalence and 
severity of ED. One of the objectives of this pilot project was that provider awareness relating to 
the use of the IIEF-5 questionnaire for ED would improve. Erectile function in this pilot project 
was determined on the patients’ score to the IIEF-5 questionnaire given by the providers in two 
clinics in southern West Virginia. Providers at both of the clinics have found the IIEF-5 
questionnaire to be a valuable, sensitive, and specific tool in the clinic. After using the 
questionnaire during the pilot project period and seeing the results, the providers believe that this 
tool will be an asset to their clinics and that their patients will benefit greatly from its use.  The 
questionnaire was found to be a simple and easy method for assessing and measuring ED. The 
ease at which the severity of ED could be established using the IIEF-5, helped support the use of 
the questionnaire. 
The evidence collected in this pilot project supports the use of a validated questionnaire 
for the diagnostic assessment of ED. Evidence collected in the four clinical practice guidelines 
(Canadian Guidelines Towards Optimized Practice [TOP], 2010; Hatzimouratidis et al., 2010; 
Kimoto et al., 2008; Montague et al., 2009), four systematic reviews (Cappelleri & Rosen, 2005; 
Markou et al., 2004; Ruiz-Aragon et al. 2010; Tsertsvadze et al., 2009), two RCTs (Hwang et al., 
2010; Shabsigh et al., 2010), and the two prospective studies (Hakim et al., 2002; Ponholzer et 
al., 2005) also supported the use of a validated questionnaire for the diagnostic assessment of 
ED.  
According to a study completed by Hader et al. (2007) there were numerous major 
influences that the physicians saw as a necessity for them to adopt an innovation. First, the 
physicians needed to know that the guidelines exist. Second, the need for change must be 
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apparent. Third, the physicians needed to know that the innovation would have positive results 
and have no risk for their patients. Finally, the patients and their families must want the change. 
During this pilot project, once the providers realized the IIEF-5 questionnaire existed, they were 
willing to use it in their clinics. The providers supported the use of the validated IIEF-5 
questionnaire and saw positive patient outcomes with no augmented risk for continuation of the 
use of the IIEF-5 questionnaire. Lastly, with 89 of the 250 patients seen during the pilot project 
period completing the questionnaire, the providers realize that their patients are accepting of 
change. This pilot project supports provider practice change as found in the literature with the 
necessities physicians are seeking in order to adopt an innovation.  
Barriers to the project.  ED in its self is a potential barrier - simply because of the 
embarrassment of the topic. According to Baldwin et al. (2003) the most common reason cited 
for the under-reporting of ED was embarrassment. Patients do not want to bring up the topic and 
wish that their primary care physician would and eliminate the need for them to do so (Baldwin 
et al., 2003). Another barrier could be that the patients just do not want to fill out another form or 
just do not want to complete the questionnaire. Other than the patients willingness to participate 
in the pilot project, another barrier could be the providers not wanting to take the time to 
implement the questionnaire and then to follow-up with the results or treatment options 
associated with ED. A potential barrier to the project might be if the providers allow their nurse 
to present and explain the IIEF-5 to the patients. If the patient feels this is an embarrassing 
subject, they may not want to discuss it with anyone but the provider. Obtaining IRB approval 
was a potential barrier, as patient consent was required.  
Limitations of the project. The sample size (n=71) was a limitation to this pilot project. 
Another limitation was the study time frame. Expanding the implementation period from six-
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weeks to three to six months would give the Project Leader time to evaluate the treatment 
options offered to the patients. The additional time would also allow the investigator to evaluate 
whether the physicians were going to adopt the practice change. Another limitation to this pilot 
project is that the national guidelines only support the use of a validated questionnaire, instead of 
making the use of the questionnaire a recommendation.  Adding the use of a validated 
questionnaire to the recommendations of the guidelines would help to ensure the success of 
future endeavors.  An additional limitation was that the post implementation patients were not 
randomly selected. Finally, a limitation to the project was that the pre and post implementation 
age groups were skewed. In the pre implementation group, there were 23/50 (46%) patients 40 - 
50 years of age, while the post implementation group had 5/71(7%) patients 40 – 50 years of age 
with a diagnosis of ED. 
Implications for Practice.  The overall mission of both clinics is to provide quality 
professional healthcare, to promote health, prevent illness, and to empower patients to manage 
their health. Both clinics are dedicated to improving the quality of health care and health 
outcomes through providing timely, innovative, and compassionate care.  With the prevalence of 
ED, utilization of the IIEF-5 in the clinic would open the door to men specifically pursuing help 
for ED. In addition, because of what ED does to the interpersonal relationships having an avenue 
to get help for ED could potentially help the couple’s relationship, thereby reducing stress, and 
depression.  The use of the IIEF-5 questionnaire for all initial new patients’ visits, as well as 
current male patient’s yearly exam would help to ensure that the providers are covering all aspect 
of the health exam.  This may let the providers discover other issues such as early cardiovascular 
disease.    
 52 
This pilot project functioned to improve assessment, diagnosis, and documentation of 
treatment plans for patients with ED. The pilot project utilized established evidence-based 
clinical guidelines and the validated IIEF-5 questionnaire to diagnose ED to enable healthcare 
providers to acknowledge the significance of diagnosing and treating ED in patients for earlier 
recognition and prevention, not only for ED but for potential cardiovascular disease. Informing 
and educating the providers on the IIEF-5 and the use of the questionnaire has increased 
awareness in ED, of the sensitivity of the subject, as well as an increase in awareness of ED 
among their patients.  
ED and potential cardiovascular disease may be reduced by utilizing the IIEF-5 
questionnaire as part of the clinics health maintenance routine.  Educating the afflicted patient 
with information on lifestyle changes can potentially reduce health care issues and provide a 
better quality of life.  
 Implication for Doctorate of Nursing Practice (DNP).  This pilot project incorporated 
the DNP essentials, utilized scientific underpinning, and evidence-based practice to promote and 
augment health care. While increasing the providers understanding and awareness of ED, this 
pilot project helped to reduce the inefficiency in under diagnosing, reporting, and treating 
patients afflicted with this condition. Utilizing the IIEF-5 questionnaire in the clinics will allow 
the providers to identify patients with ED, document a diagnosis of ED, and offer treatment 
options based on evidence-based research and clinical practice guidelines.  Establishing a 
provider practice change was the core of this pilot project. Increasing concerted relationships 
with the providers will garner continual sponsorship in resolving this healthcare problem.  
Following the evidence-based research and clinical practice guidelines will promote healthy 
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outcomes and prevention of chronic illnesses, thus in direct correlation future financial impact 
will be diminished.  
Recommendations  
 Continuing education on the clinical practice guidelines and evidence-based research on 
ED may help prevent cardiovascular disease. This pilot project opens the door to future 
endeavors in the area of ED in southern West Virginia and elsewhere in the country. One 
recommendation would be to extend the project out for a three, six, or twelve month period.  In 
the clinic it would be prudent to use the IIEF-5 questionnaire during the male patient’s yearly 
health exam and increase the age range to screen males 30 to 80 years of age, regardless of a 
previous diagnosis. With the possible correlation between ED and cardiovascular disease, a 
recommendation is to longitudinally follow all the patients in this pilot study with a diagnosis of 
ED, to evaluate their future cardiovascular disorders. Using the IIEF-5 questionnaire as follow-
up for the evaluation of treatment is another recommendation for the clinics. With the use of the 
EMR systems it would be fairly easy to run a data search categorizing: male patient, 30 to 80 
years of age, and with an ICD-9 code for ED, therefore, a recommendation would be to search 
the clinics complete database instead of a random selection.  
Conclusion 
 In conclusion, this pilot project provides estimates on the prevalence of ED utilizing the 
IIEF-5 questionnaire in two clinics in southern West Virginia. As previously discussed in this 
paper, the IIEF-5 questionnaire had been found to be effective in improving diagnosis, 
documentation, and treatment of ED (Feldman et al., 1994) but was not previously used in 
primary care clinics. Consequently, this intervention was utilized to evaluate the effectiveness of 
the IIEF-5 questionnaire on the diagnosis and treatment of ED in these clinics. The objectives 
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were clearly stated and the instruments used to gauge the objectives are described in the 
literature as valid and reliable. 
The findings from this pilot project support provider behavior change for the improved 
assessment and diagnosing of ED, as well as the documentation of treatment options offered.  
Assessment for ED, using the IIEF-5, should be completed on all male patients, 40 to 70 years of 
age with specific co-morbidities. Primary care providers should be screening their patients as 
effective treatment for ED is obtainable and because ED has been related to cardiovascular 
disease. This pilot project has built a foundation for future research on evaluation of provider 
behavior change and utilization of the validated IIEF-5 questionnaire for assessment of ED and 
documentation of treatment option. ED is a preventable health issue in males which is presently 
under estimated and under reported by patients, as well as under diagnosed and treated by 
providers.  
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Figure 1 
Five Stages in the Decision Innovation Process 
   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Source of information: Rogers (2003) 
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Appendix A: IIEF-5                                           No. _____ 
International Index of Erectile Function 5 (IIEF-5)/ SHIM 
Each question has several possible responses. Circle the number of the response that best 
describes your own situation. Please be sure that you select one and only one for each question. 
OVER THE PAST 6 MONTHS: 
1. How do you rate your confidence that you could get and keep an erection? 
2. When you had erections with sexual stimulation, how often were your erections hard enough 
for penetration (entering your partner)? 
3. During sexual intercourse, how often were you able to maintain your erection after you had 
penetrated (entered) your partner? 
4. During sexual intercourse, how difficult was it to maintain your erection to completion of 
intercourse? 
 5. When you attempted sexual intercourse, how often was it satisfactory for you? 
 
None Very Low Low 
Low  
Moderate 
High 
Very  
High 
      
0 1 2 3 4 5 
No sexual 
activity  
Almost 
never or 
never  
A few times 
(much less 
than 1/2 the 
time) 
Sometimes 
(about ½ the 
time) 
Most times 
(much more 
than ½ the 
time) 
Almost 
always or 
always 
      
0 1 2 3 4 5 
Did not 
attempt 
intercourse 
Almost 
never or 
never  
A few times 
(much less 
than 1/2 the 
time) 
Sometimes 
(about ½ the 
time) 
Most times 
(much more 
than ½ the 
time) 
Almost 
always or 
always 
      
0 1 2 3 4 5 
Did not 
attempt 
intercourse 
Almost 
always or 
always  
Most times 
(much more 
than ½ the 
time) 
Sometimes 
(about ½ the 
time) 
A few times 
(much less 
than 1/2 the 
time) 
Almost 
never or 
never 
      
0 1 2 3 4 5 
Did not 
attempt 
intercourse 
Almost 
never or 
never  
A few times 
(much less 
than 1/2 the 
time) 
Sometimes 
(about ½ the 
time) 
Most times 
(much more 
than ½ the 
time) 
Almost 
always or 
always 
      
0 1 2 3 4 5 
 63 
Appendix A: cont. 
 
SHIM Questionnaire (Sexual Health Inventory for Men) or IIEF-5        Date: __________ 
 
IIEF-5 Questionnaire Number __________                                    Patient Score: ___________ 
The Sexual Health Inventory for Men further classifies Erectile Dysfunction (ED) severity with 
the following:   
 
0-7 Severe ED   
 
8-11 Moderate ED    
 
12-16 Mild to Moderate ED    
 
17-21 Mild ED  
 
22-25 Normal 
 
 
*Was the IIEF-5 discussed with the patient?    
 
Was the score discussed with the patient?       
 
Were treatment options offered?      
 
Was a follow-up appointment scheduled?     
 
 
 
 
 
 
 
 
 
 
 
 
 
With Permission - Source: Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A.  
The international index of erectile function (IIEF) a multidimensional scale for assessment of 
ED. Urology. 1997 Jun; 49(6):822-30. Copyright 1997 by Elsevier Science, Inc. 
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Appendix B: Letter of Approval 
 
  
 65 
Appendix B: Letter of Approval cont. 
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Appendix C: Letter of Approval
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Appendix D: Demographics/Cover page                                                  No. _______ 
This is a project to look at adding a questionnaire to this practice to see if it will help you 
and your doctor find out if you have ED. This will also let you discuss the different treatment 
choices with your doctor, if you want to. I appreciate your time in filling out the following 
questions. In completing this project, I hope that you and your doctor will be able to better meet 
your needs. The information collected here will remain private. Please DO NOT put your name 
on any part of the questionnaire.  
 
Age:        – 40yrs.  – 50 yrs.    
 – 60 yrs.     – 70 yrs.                – 80 yrs. 
Race:                
Marital status:                 
                         
Place an X in the box if your doctor told you that you have any of the following - Please 
check all that apply.  
 
  
      
     
Hyperlipidem   
     
 Alcohol       
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Appendix E: Data Collection Form 
 
Patient number: _______           Age: _________ 
Medications: __________________________________________________________________ 
_____________________________________________________________________________ 
 
Co-morbidities and Risk Factors: __________________________________________________ 
_____________________________________________________________________________ 
Does the patient have a documented diagnosis of ED: Yes    No    Unknown  
 
Diagnostic laboratory tests for the diagnosis of ED (mark with X when completed): 
 
Liver hepatic function panel      Lipid profile    Thyroid function study   
 
Urine analysis           Creatinine    Glucose level    
 
Prostate specific antigen (PSA)   Complete blood count   
 
Serum testosterone hormone level (free or total)  
 
To assess pituitary function when the serum testosterone level is low:  
 
Gonadotropin follicle stimulating hormone   Gonadotropin luteinizing Serum prolactin  
 
Are they on or do they use a treatment for ED: 
 
If yes, what type of treatment: ________________________ 
 
If yes, what are the results: satisfactory unsatisfactory      Unknown 
 
Is there follow-up to evaluate treatment: Yes  No 
 
If yes, is it in an appropriate timeframe - 3 months:  Yes  No 
 
If no, is there a documented reason why:   Yes  No 
 
Did patient do recommended follow-up:    Yes  No  Unknown 
 
Is the patient satisfied with their current treatment?               Yes      No Unsure 
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Appendix F: Timeline 
 
  
30 
30 
60 
60 
60 
30 
35 
60 
15 
15 
45 
45 
30 
30 
60 
60 
60 
15 
IIEF-5-Questionnaire
Education Plan
Demographics/Cover
Data Collection Form
Marketing/Budget
Capstone Power Point
Capstone Presentation
IRB
Provider Education
Baseline Data
Implementation
Weekly Calls/B-…
Post-Intervention Data
Evaluation/Alalysis
Finalize Paper
Share Results with Sites
Capstone Presentation
Graduation
# Days
         Jun     Jul     Aug   Sep    Oct    Nov    Dec    Jan     Feb    Mar   Apr   May 
Evaluation of a Pilot Project using the IIEF Questionnaire 
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Appendix G: Budget 
 
Financial                             Cost 
IIEF-5 questionnaire                          ($1.33423 = 1€) 300€ ($400.27) to 600€            $    00.00 
            ($800.54) per study with 50€ ($66.71) to 250€ ($333.56) per language  
Physicians time $   00.00        $    00.00 
Power point for lunch and learn         $    55.00     NP time ½ hour each x 2                  $   00.00 
Space at clinics              $    00.00                      $   00.00 
Lunch for Education program            $   100.00                    $ 100.00 
Christmas Baskets for clinic sites post implementation                                           $    42.29  
 
Copies of Questionnaire                     $   143.73 @ $0.09 per page 500 copies               $ 143.73 
                1 one-sided and 2 two-sided pages, pens, staples, staples, and labels  
                from Staples                                                    
 
Gas for 4 trips to clinics –  
696 miles @ 3.75 gallon                     $   255.00                      $ 255.00 
Medical assistant/nurse                       $    93.30 (donated by the clinics)                       $   00.00  
__________________________________________________________________________ 
                                                                                                       Total Pilot Project Cost $541.02  
Faculty Grant in the amount of $500.00 was obtained for this DNP project, therefore total cost to 
the investigator was:                   $  41.02 
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Appendix H: Log Sheet 
 NAME DOB IIEF-5 NO. 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
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 NAME DOB IIEF-5 NO. 
26    
27    
28     
29    
30    
31    
32    
33    
34    
35    
36    
37    
38    
39    
40    
41    
42    
43    
44    
45    
46    
47    
48    
49    
50    
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Appendix I: Content Outline 
Summary of Education Training for the Providers on the Evaluation of the Effectiveness of the 
International Index of Erectile Function (IIEF-5) Questionnaire  
ED  
Also known as “impotency” 
Defined as the failure to reach and/or maintain an erection for satisfactory sexual 
performance 
Most common sexual disorder in men 
Anxiety, low self-esteem, low self-confidence, and difficulty with interpersonal 
relationships 
Significance of Problem  
ED affects 52% or approximately 30 million men in the United States between 40 and 70 
years of age  
ED is growing from 5% among men age 40 to 15% among those 70 years of age 
Conservative worldwide projection of ED is 322 million cases by 2025  
Relevant databases  
National Guideline Clearinghouse (NGC) 
Cochrane Library 
Cumulative Index of Nursing and Allied Health Literature (CINAHL) 
PubMed 
Science Direct
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Appendix I: Content Outline 
Academic Search Complete 
Google Scholar 
Literature search  
Key words: Erectile function, International Index of Erectile Function (IIEF-5), erectile 
dysfunction, diagnosis, treatment, practice change, screening, evaluation, clinical setting, and 
provider behavior change  
Search Strategy  
Narrowed articles: 
• Recent < 7 years old 
• Human studies 
• Peer reviewed journals 
• Available in English 
15 studies were reviewed for this project 
Relevant Literature  
Five clinical practice guidelines 
Four systematic reviews 
Three randomized controlled trials 
Two prospective studies 
Non-experimental descriptive study 
National Benchmarks for ED  
There have been no specific benchmarks developed for ED  
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Appendix I: Content Outline 
Synthesis of the Literature  
Evidence collected through the review of the 15 articles supports the use of a validated 
questionnaire for the diagnosis of ED 
Evidence from all five clinical practice guidelines, two systematic reviews, and one RCT 
support the use of the PDE-5 inhibitors for the treatment of ED as first line therapy  
Synthesis of the Literature - Gaps  
Gaps exist in the evidence about treatment specific agents and long-term consistency of 
the PDE-5 inhibitors over time  
While four of the clinical practice guidelines support the use of a validated questionnaire, 
only one includes a validated questionnaire as a recommendation  
Main Goal of the Project  
To evaluate a pilot project to incorporate the IIEF-5 questionnaire into the patient’s chart 
to increase the diagnosis and documentation of treatment options for ED when indicated 
by the score on the questionnaire 
PICOT  
Does provider education and the use of the IIEF-5 questionnaire increase diagnosis of ED 
and documentation of treatment options, in southern West Virginia? 
Hypotheses  
The use of the IIEF-5 questionnaire in the clinical practice will increase the diagnosis of 
ED    
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Appendix I: Content Outline 
The use of the IIEF-5 questionnaire in the clinical setting will increase the documentation 
of the discussion of treatment options for men with ED  
To orient the physicians and staff at two sites on the use of the IIEF-5 questionnaire 
between October 15, 2012 and November 1, 2012 
To evaluate a baseline number of patients with a diagnosis of ED in each clinic by doing 
a  pre intervention chart review of 50 randomly selected male patient charts between 
October 15, 2012 and November 1, 2012  
Objectives  
To determine the number of patients with ED in post intervention randomized samples by 
September 30, 2012  
To evaluate the inclusion of the IIEF-5 questionnaire in the medical record for every male 
patient > 18 years of age during the eight-week pilot project 
To have an increase in documentation of discussion and treatment options offered to 
patients with ED from baseline to post incorporation of the questionnaire by 10%  
Clinical Site  
Dr. Elizabeth L. Brown – General Internist 
Private practice in Charleston, West Virginia 
Dr. Kelly Pitsenbarger – Family Practice 
Private practice in Beckley, West Virginia  
References Provided on Request 
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Appendix K: PowerPoint Presentation (available as a separate download, in full) 
 
